- The stock price of Alimera Sciences Inc (NASDAQ: ALIM) increased by over 6% today. This is why it happened.
The stock price of Alimera Sciences Inc (NASDAQ: ALIM) – a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and to maintain better vision longer – increased by over 6% today. Investors are responding positively to Alimera Sciences announcing a data presentation at the American Society of Retina Specialists (ASRS). This presentation demonstrated significant reductions in treatment burden in patients receiving ILUVIEN for Diabetic Macular Edema (DME).
This real-world data from the Phase 4 PALADIN study show that patients receiving one or less total injections per year for their DME after the ILUVIEN injection increased 3-fold from prior to the ILUVIEN injection. And the data also show that the percent of patients who needed more than four DME treatments per year was reduced by 50%.
The abstract presented by Dr. Victor Gonzalez, lead author, presenter, and Retina Specialist at Valley Retina Institute, had analyzed a subset of 83 eyes from Alimera’s PALADIN Study for which the company was able to collect data for 24 months both pre- and post-ILUVIEN injection. And for this analysis, this subset was divided based on the number of supplemental treatment events (including laser, intravitreal anti-VEGF, and steroid) per year before and after receiving ILUVIEN. This data was presented during the 39th annual scientific meeting of the ASRS October 8-12, 2021, in San Antonio, Texas.
The PALADIN Study is a 3-year prospective observational Phase IV study of 0.19mg FAc (ILUVIEN) based in the US with focus on safety outcomes in patients with DME treated according to the US FDA label. And the NEW DAY Study is a multicenter, single-masked, randomized, controlled trial designed to generate prospective data evaluating ILUVIEN as a baseline therapy in the treatment of DME and demonstrate its potential advantages over the current standard of care of repeat anti-VEGF (aflibercept) injections.
The primary outcome measure for NEW DAY is the mean number of supplemental aflibercept injections needed during the trial between treatment groups. And the key secondary endpoints include mean best-corrected visual acuity (BCVA) score over time up to 18 months, time to first supplemental treatment, retinal thickness amplitude on optical coherence tomography (OCT), and diabetic retinopathy scores. Dr. Gonzalez is the principal investigator.
KEY QUOTE:
“These data demonstrate a significant reduction in treatments in patients with DME after receiving ILUVIEN, supporting the premise of our NEW DAY Study. In the NEW DAY Study, we believe that ILUVIEN, due to its long-term durability and anti-inflammatory properties, can significantly reduce the need for frequent and recurring injections compared to the leading anti-VEGF.”
— Dr. David Dyer, Alimera Sciences’ Chief Retina Specialist
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.
